CJC-1295 raises growth hormone and IGF-1 in humans. That part is real, measured, and published. What is not real is everything built on top of it: the muscle gains, the fat loss, the sleep and skin claims that fill every research-chemical listing. The gap between what the 2006 trial showed and what the marketing promises is the entire story here, and it is wider than most peptide writeups admit.
What the 2006 dosing trial measured
The core human evidence on CJC-1295 comes from a small number of published studies. It is anchored by one placebo-controlled, ascending-dose trial in healthy adults, the only study to characterize its hormone pharmacodynamics directly.[1]
The design: researchers ran two randomized, double-blind, placebo-controlled trials. The first tested four ascending single subcutaneous doses in healthy adults aged 21 to 61. The second gave two or three repeated weekly or biweekly doses over a longer stretch, up to 49 days.[1]
5.8-8.1 days estimated half-life of CJC-1295, versus minutes for native GHRH PMID 16352683
A single injection produced dose-dependent increases in growth hormone lasting six days or more, and IGF-1 increases lasting nine to eleven days. Repeated dosing kept IGF-1 elevated above baseline for up to 28 days, a cumulative effect the authors flagged directly.[1]
That is a genuinely long-acting hormone response from a single shot. It is also, so far, the only thing anyone has rigorously shown CJC-1295 does.
Why this counts as evidence, not internet lore
The dosing trial used a controlled, interventional design: researchers gave a known dose and tracked what happened afterward. That is a different animal from an observational study of people who already inject CJC-1295 and report how they feel.
An interventional trial like this can support a causal claim. The hormone changes measured were not confounded by whatever else self-selected users happen to also be doing (training harder, eating differently, taking other compounds). Observational reports never get to make that claim, no matter how many forum posts pile up behind them.
But look closely at what was measured. The trial’s own stated outcomes were growth hormone and IGF-1 concentrations and standard pharmacokinetic parameters.[1] It did not track a clinical outcome like muscle mass, strength, fat loss, or a diagnosed disease endpoint.
The surrogate marker problem: a hormone going up on a blood test is not the same claim as a body changing shape. Plenty of compounds raise a biomarker without ever being shown to produce the downstream outcome people want.
The mechanism: confirmed, and still marketing
CJC-1295 is described in the literature as a long-acting analog of growth hormone-releasing hormone (GHRH) that acts on the same pituitary somatotrope receptors as natural GHRH to stimulate growth hormone release.[2] A related 2009 study gave CJC-1295 to 11 healthy young men and ran their serum through two-dimensional gel electrophoresis a week later, finding shifts in proteins including an apolipoprotein A1 isoform, a transthyretin isoform, and fragments of albumin itself, changes the authors linked to the GH/IGF-1 axis activation.[2]
Here is where the marketing gets ahead of the science. CJC-1295 is sold under the banner of “DAC,” short for Drug Affinity Complex, with sellers explaining that this chemistry covalently binds circulating albumin to stretch the molecule’s action from minutes to days.
I could not find a peer-reviewed source in the primary literature confirming that specific chemistry for CJC-1295. What the 2006 trial confirms directly is the outcome, a measured half-life of 5.8 to 8.1 days. It says nothing about the mechanism producing that half-life.
That gap matters less for the pharmacokinetics (the half-life was measured, full stop) and more for anyone trying to reverse-engineer how the compound behaves from a mechanism nobody has independently verified in a journal. Compare that to insulin detemir and insulin degludec, long-acting insulin analogs where a fatty acid tail attached to the hormone binds albumin by design, extending action from hours to a full day. That chemistry is documented and reproducible across dozens of studies. CJC-1295’s version of the same trick rests on manufacturer claims the published literature has not independently confirmed.
Downstream effects attributed to CJC-1295, like increased muscle protein synthesis or fat loss, are extrapolated from the general physiology of growth hormone and IGF-1. Nobody has demonstrated them directly with CJC-1295 in a controlled human study.
The doses that were tested
What the 2006 trial reported, by dosing schedule
Regimen | Growth hormone | IGF-1 |
|---|---|---|
Single subcutaneous dose | 2- to 10-fold increase, lasting 6+ days | 1.5- to 3-fold increase, lasting 9-11 days |
Repeated dosing (weekly/biweekly) | Not broken out separately in the published results | Stayed above baseline for up to 28 days |
Ascending single doses in study one; repeated weekly or biweekly doses in study two.
The trial found CJC-1295 was safe and relatively well tolerated in healthy adults, with no serious adverse events, particularly at the 30 and 60 microgram per kilogram doses tested.[1] Those are the two numbers that show up in a real journal. Everything else, the 100 mcg, 300 mcg, and 2 mg protocols that circulate on research-chemical forums, comes from nowhere a citation can trace back to.
The doses and injection frequency the trial studied do not match the varied, often higher-dose regimens marketed for CJC-1295 online. Nobody ran the 2006 protocol against what people are injecting.
Side effects, and the safety record that doesn’t exist
What the trial reported: no serious adverse events, and a description of the compound as safe and relatively well tolerated at the doses tested.[1] That is a real, if narrow, safety signal.
What nobody has looked at:
Duration. No published human trial of CJC-1295 has followed participants for more than a few months. Anything about long-term effects on insulin sensitivity from sustained IGF-1 elevation is unstudied territory, not a documented risk or a documented safety record.
Product purity. CJC-1295 is not an approved drug. Products sold under that name are not subject to the purity and dosing controls that apply to prescription growth hormone therapies. A vial labeled CJC-1295 is only as trustworthy as the seller behind it.
Bottom line on safety: the safety record covers a few weeks under research conditions. Nobody has data on years of use, and nobody can vouch for what arrives in an unregulated seller’s vial.
What the trial never tested
No published human trial has measured whether CJC-1295 changes body composition, athletic performance, or injury recovery, the exact outcomes most often cited in marketing for the peptide. The 2006 trial measured hormones in blood. It never measured bodies in mirrors.
Claims that CJC-1295 improves sleep quality, skin appearance, or longevity rest on the general physiology of growth hormone rather than on any trial of CJC-1295 measuring those outcomes specifically. Growth hormone does plenty of documented things in the body. None of that is the same as CJC-1295 doing those things, tested and confirmed.
CJC-1295 is not approved by the FDA or the European Medicines Agency for any indication, and it does not appear as an active drug in major human trial registries beyond the original dose-finding work. There is no pipeline behind it, no phase III program, nothing suggesting a company is trying to turn this into an approved therapy.
Where CJC-1295 fits against tesamorelin
If you want to see what a real development program for a GHRH analog looks like, look at tesamorelin. It has been tested in phase III randomized, placebo-controlled trials enrolling hundreds of patients with HIV-associated abdominal fat accumulation, a substantially larger human trial base than CJC-1295’s single small dose-finding study.[3] One of those trials ran 404 HIV-infected patients through 12 months of daily 2 mg tesamorelin against placebo, with a safety extension phase built into the design.[3]
Read what tesamorelin’s own trial record supports and the contrast is stark: a defined patient population, a specific dose, a full year of follow-up, hundreds of subjects. CJC-1295 has none of that. It has one small pharmacodynamic study confirming the hormone changes work, and a research-chemical market that has run far ahead of what anyone has proven.
Against that backdrop, CJC-1295’s evidence base remains a single dose-finding study in healthy adults. That is thinner than the trial record behind the GHRH analog that cleared regulatory approval.
If you are comparing CJC-1295 against the peptide it is most often stacked with, the pharmacology of CJC-1295 and ipamorelin together tells its own, separate story about missing outcomes, and a broader rundown of how CJC-1295 stacks up against other options is worth reading in full.
The one paragraph that matters
CJC-1295 raises growth hormone and IGF-1 for days after a single shot, in a real, placebo-controlled, published trial. That is not nothing. But it is also the entire published human record.
Nobody has shown it builds muscle, burns fat, improves sleep, or does any of the things it is sold for, and the “DAC” mechanism explaining its long action has not been independently confirmed in the literature I could locate. A hormone going up on a blood test, for a few weeks, in a small trial from 2006, is the whole foundation. Everything stacked on top of that foundation is extrapolation wearing a lab coat.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.. The Journal of clinical endocrinology and metabolism, 2006.
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009.
Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.. Journal of acquired immune deficiency syndromes (1999), 2010.
